RDEA119 and Sorafenib Combination Dose Escalation Study

Completed · Phase 1/Phase 2

Conditions studied: Advanced Cancer

In brief

Phase 1/2 dose escalation study to investigate the combination of RDEA119 and sorafenib in advanced cancer patients.

Key facts

Study ID

NCT00785226

Run by

Bayer

People needed

62

Starts

2008-11-01

Expected to finish

2012-04-01

Last updated by the study team

2016-10-17

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• USC/Norris Comprehensive Cancer Center and LAC/USC Medical Center — Los Angeles, California, United States
• Comprehensive Cancer Centers of Nevada — Las Vegas, Nevada, United States
• New York Oncology Hematology, PC — Albany, New York, United States
• Roswell Park Cancer Institute — Buffalo, New York, United States
• James P. Wilmot Cancer Center — Rochester, New York, United States
• UPenn — Philadelphia, Pennsylvania, United States
• Greenville Hospital System University Medical Center, (ITOR) — Greenville, South Carolina, United States
• Texas Oncology - Baylor Charles A. Simmons Cancer Center — Dallas, Texas, United States
• Texas Oncology-Tyler — Tyler, Texas, United States
• Toronto General Hospital — Toronto, Ontario, Canada

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.